Evidence map›Paper›PMID 39237680›Full record

Observational studyProstate cancer and prostatic diseases2025

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.

Lauren Lenz, Wyatt Clegg, Diana Iliev, Chelsea R Kasten, Howard Korman, Todd M Morgan, Jason Hafron, Alexander DeHaan, Carl Olsson, Ronald F Tutrone and 8 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment.International journal of molecular sciences · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lauren LenzMyriad Genetics, Inc., Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-1957-1068
Wyatt CleggMyriad Genetics, Inc., Salt Lake City, UT, USA.
Diana IlievMyriad Genetics, Inc., Salt Lake City, UT, USA.
Chelsea R KastenMyriad Genetics, Inc., Salt Lake City, UT, USA.
Howard KormanComprehensive Urology, Royal Oak, MI, USA.
Todd M MorganUniversity of Michigan, Ann Arbor, MI, USA.ORCID http://orcid.org/0000-0002-1140-0603
Jason HafronMichigan Institute of Urology, Troy, MI, USA.
Alexander DeHaanUrologic Consultants, Wyoming, MI, USA.
Carl OlssonIntegrated Medical Professionals, Melville, NY, USA.
Ronald F TutroneChesapeake Urology, Towson, MD, USA.
Timothy RichardsonWichita Urology, Pratt, KS, USA.
Kevin ClineRegional Urology, Shreveport, LA, USA.
Paul M YonoverUroPartners, Chicago, IL, USA.
Jeff JasperMyriad Genetics, Inc., Salt Lake City, UT, USA.
Todd CohenMyriad Genetics, Inc., Salt Lake City, UT, USA.
Robert FinchMyriad Genetics, Inc., Salt Lake City, UT, USA.
Thomas P SlavinMyriad Genetics, Inc., Salt Lake City, UT, USA.
Alexander GutinMyriad Genetics, Inc., Salt Lake City, UT, USA. agutin@myriad.com.ORCID http://orcid.org/0000-0002-6565-3729

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenomic testing can add risk stratification information to clinicopathological features in prostate cancer, aiding in shared medical decision-making between the clinician and patient regarding whether active surveillance (AS) or definitive treatment (DT) is most appropriate. Here we examined initial AS selection and 3-year AS durability in patients diagnosed with localized intermediate-risk prostate cancer who underwent Prolaris testing before treatment decision-making.

methodsThis retrospective observational cohort study included 3208 patients from 10 study sites who underwent Prolaris testing at diagnosis from September 2015 to December 2018. Prolaris utilizes a combined clinical cell cycle risk score calculated at diagnostic biopsy to stratify patients by the Prolaris AS threshold (below threshold, patient recommended to AS or above threshold, patient recommended to DT). AS selection rates and 3-year AS durability were compared in patients recommended to AS or DT by Prolaris testing. Univariable and multivariable logistic regression models and Cox proportional hazard models were used with molecular and clinical variables as predictors of initial treatment decision and AS durability, respectively.

resultsAS selection was ~2 times higher in patients recommended to AS by Prolaris testing than in those recommended to DT (p < 0.0001). Three-year AS durability was ~1.5 times higher in patients recommended to AS by Prolaris testing than in those recommended to DT (p < 0.0001). Prolaris treatment recommendation remained a statistically significant predictor of initial AS selection and AS durability after accounting for CAPRA or Gleason scores.

conclusionsProlaris added significant information to clinical risk stratification to aid in treatment decision making. Intermediate-risk prostate cancer patients who were recommended to AS by Prolaris were more likely to initially pursue AS and were more likely to remain on AS at 3 years post-diagnosis than patients recommended to DT.

Indexed as

Biomarkers, TumorGenetic TestingProstatic NeoplasmsWatchful WaitingAgedFollow-Up StudiesGenomicsHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentBiomarkers, Tumor

Identifiers

PMID39237680
PMCPMC12106071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.